Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380454 | 0.93 | ALDH1A1 (0.58) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2185822 | 0.92 | RAB9A (0.59) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3380826 | 0.91 | LMNA (0.60) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3377521 | 0.90 | LMNA (0.59) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3379800 | 0.89 | LMNA (0.58) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2186493 | 0.88 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTHDAC2HDAC8 | |
| SCHEMBL3378933 | 0.88 | MAPT (0.59) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3377290 | 0.88 | LMNA (0.57) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3376241 | 0.87 | LMNA (0.61) | ALDH1A1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL3379886 | 0.85 | LMNA (0.59) | ALDH1A1LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | claimed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | claimed |
| JP-2012500836-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2342177-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-07-13 | — | — | EP | claimed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | claimed |
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | ALDH1A1 1360/4885RAB9A 1923/4885NPC1 628/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | ALDH1A1 3795/4885RAB9A 3852/4885NPC1 905/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | ALDH1A1 1360/4885RAB9A 1923/4885NPC1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.